NASDAQ · VIR
Vir Biotechnology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VIR: Nov 04, 2026
Vir Biotechnology, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.8. The reported EPS for the same quarter last year was $-1.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.80 | $-0.55 | $-1.02 | 5 |
| Dec 2026 | $-0.76 | $-0.62 | $-0.89 | 4 |
| Mar 2027 | $-0.66 | $-0.54 | $-0.77 | 2 |
| Jun 2027 | $-0.68 | $-0.61 | $-0.75 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · The Motley Fool- Zacks · Oct 29, 3:50 AM EDTBeam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Fintel · Oct 28, 2:59 PM EDTVir Biotechnology, Inc. Appoints Suzanne Topalian, M.D., to Board of DirectorsOn October 26, 2026, the Board of Directors of Vir Biotechnology, Inc. approved an increase in the size of the Board from eight to nine members. The Board appointed Suzanne Topalian, M.D., to fill the newly created vacancy and serve as a Class III director until the Company&rsquo
- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- Zacks · Oct 15, 1:17 PM EDTCan Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
- RTTNews · Oct 14, 11:06 AM EDTVir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs(RTTNews) – Vir Biotechnology, Inc. (VIR) has entered into a multi-program collaboration and license agreement with Gilead Sciences (GILD) to discover and develop three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associate
- RTTNews · Aug 13, 7:17 AM EDTOlema Appoints Jason O'Byrne As CFO(RTTNews) – Olema Pharmaceuticals Inc. (OLMA), a clinical-stage biopharmaceutical company, on Thursday appointed Jason O'Byrne as Chief Financial Officer.
- The Motley Fool · Aug 12, 5:28 PM EDTVir Biotechnology (VIR) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 3:03 AM EDTVir Biotechnology Q2 Earnings Call HighlightsFrom laggards to leaders: Small caps on the riseVir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data re
- Zacks · Aug 5, 8:35 PM EDTVir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss EstimatesVir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 26, 12:04 PM EDTJade Biosciences Appoints Mark Eisner To The Board Of Directors(RTTNews) – Jade Biosciences, Inc. (JBIO) announced the appointment of Mark Eisner to its Board of Directors, effective June 25, 2026.
- The Motley Fool · May 23, 6:33 PM EDTWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallySuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices.
- The Motley Fool · May 18, 11:19 AM EDTVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionSB Investment Advisers sold 2,168,884 shares of Vir Biotechnology in the first quarter; the estimated transaction value was $17.28 million.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vir Biotechnology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.